PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Our goal is to accelerate pre-clinical drug discovery by developing novel imaging assays to screen and optimize the delivery of targeted anti-cancer drugs. Fluorescence lifetime imaging (FLI) Forster Resonance Energy Transfer (FRET) acts as a direct reporter of drug-target engagement in live mice carrying HER2-overexpressing tumor xenografts. We have established near-infrared (NIR) Macroscopy FLI FRET (MFLI-FRET) non-invasive imaging approach to measure drug-target engagement in deep tissues. We used trastuzumab (TZM), an anti-HER2 antibody clinical drug, as NIR-labeled FRET probes to assess quantitatively the role of tumor microenvironment on drug-target binding and penetration in tumor xenografts.
Amit Verma,Vikas Pandey,Jason T. Smith,Xavier Intes, andMargarida Barroso
"Impact of tumor microenvironment in antibody-HER2 binding using macroscopy fluorescence lifetime FRET in vivo imaging", Proc. SPIE 12357, Visualizing and Quantifying Drug Distribution in Tissue VII, 123570D (17 March 2023); https://doi.org/10.1117/12.2650382
ACCESS THE FULL ARTICLE
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Amit Verma, Vikas Pandey, Jason T. Smith, Xavier Intes, Margarida Barroso, "Impact of tumor microenvironment in antibody-HER2 binding using macroscopy fluorescence lifetime FRET in vivo imaging," Proc. SPIE 12357, Visualizing and Quantifying Drug Distribution in Tissue VII, 123570D (17 March 2023); https://doi.org/10.1117/12.2650382